Increased plasma ceruloplasmin levels in schizophrenia

Klinik Psikofarmakoloji Bulteni

Volumn 18, Issue 4, 2008, Pages 282-287

  Virit, Osman ^a   Altindag, Abdurrahman ^a   Selek, Sahabettin ^b   Yumru, Mehmet ^c   Bulut, Mahmut ^a   Erel, Ozcan ^b   Savas, Haluk Asuman ^b   Herken, Hasan ^d  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b HARRAN UNIVERSITY   (Turkey)

^c Patnos State Hospital Agri   (Turkey)

^d PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Ceruloplasmin; Gender difference; Schizophrenia

Indexed keywords

CERULOPLASMIN; HEPARIN; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CENTRIFUGATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA;

EID: 58549108435     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Vassiliev V, Harris ZL, Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 2005; 49:633-640
2. Abood LG, Gibbs FA, Gibbs E. Comparative study of blood ceruloplasmin in schizophrenia and other disorders. AMA Arch Neurol Psychiatr 1957; 77: 643-645
3. Puzynski S, Kalinowski A. Investigations of some physiobiochemical properties of ceruloplasmin in schizophrenics and in normal subjects. Nature 1966; 212: 399-400
4. Puzynski S. Investigations on ceruloplasmin in chronic schizophrenia. Pol Med J 1966; 5: 1484-1491
5. Alias AG, Vijayan N, Nair DS, Sukumaran M. Serum ceruloplasmin in schizophrenia: significant increase in acute cases especially in catatonia. Biol Psychiatry 1972; 4: 231-238
6. Giner J, Morell M, Osorio C. Serum levels of ceruloplasmin as an index of the clinical evolution in schizophrenic patients. Rev Esp Fisiol 1972; 28: 39-42
7. Chugh T, Dhingra R, Gulati R, Bathla J. Copper metabolism in schizophrenia. Indian J Med Res 1973; 61: 1147-1152
8. Domino EF, Krause RR, Thiessen MM, Batsakis JG. Blood protein fraction comparisons of normal and schizophrenic patients. Arch Gen Psychiatry 1975;32:717-721.
9. Rahman B, Rahman MA, Hassan Z. Variation of copper and ceruloplasmin levels with liver function tests in schizophrenic patients. Biomedicine 1978; 29: 238-241
10. Bock E, Weeke B, Rafaelsen OJ. Serum proteins in acutely psychotic patients. J Psychiatr Res 1971; 9:1-9
11. Seal US, Eist H. Elevation of serum protein-bound carbohydrates and haptoglobin in schizophrenia. Clin Chem 1966; 12: 709-716
12. Morera AL, Henry M, García-Hernández A, Fernández-López L. Acute phase proteins as biological markers of negative psychopathology in paranoid schizophrenia. Actas Esp Psiquiatr 2007;35:249-252
13. Wolf TL, Kotun J, Meador-Woodruff JH. Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia. Schizophr Res 2006;86:167-171
14. Gaffney D, Fell GS, O'Reilly DS. ACP Best Practice No 163. Wilson's disease: acute and presymptomatic laboratory diagnosis and monitoring. J Clin Pathol 2000; 53: 807-812
15. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS. Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine clinical practice. Clin Chem 2005; 51:1558-1559
16. Bowman MB, Lewis M. The copper hypothesis of schizophrenia: a review. Neurosci Biobehav Rev 1982; 6: 321-328
17. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029-1034
18. Dumoulin MJ, Chahine R, Atanasiu R, Nadeau R, Mateescu MA. Comparative antioxidant and cardioprotective effects of ceruloplasmin, superoxide dismutase and albumin. Arzneimittelforschung 1996;46:855-861
19. Overall J, Gorham D. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799-812
20. Kay SR, Fiszbein PS, Opler LA. The positive and negative syndrome scale (PANNS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
21. Guy W. Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ. No. ADM 76-338). National Institute of Mental Health: Rockville, MD. 1976; pp 218-222
22. Erel O. Automated measurement of serum ferroxidase activity. Clin Chem 1998; 44: 2313-2319
23. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Biochem 2004; 37: 112-119
24. Martens S, Valbo S, Melander B. Studies on the role of ceruloplasmin in schizophrenia. Int Rev Neurobiol 1959; 1: 333-342
25. Pfeiffer CC, Iliev V. A study of zinc deficiency and copper excess in the schizophrenias. Int Rev Neurobiol Suppl 1972; 1: 141-165
26. Wrona MZ, Dryhurst G. Interactions of 5-hydroxytryptamine with oxidative enzymes. Biochem Pharmacol. 1991;41:1145-1162
27. Jones CE, Underwood CK, Coulson EJ, Taylor PJ. Copper induced oxidation of serotonin: analysis of products and toxicity. J Neurochem 2007;102: 1035-1043
28. Anil Yagcioǧlu AE. The mechanisms of action of antipsychotic drugs: is atypicality superior in schizophrenia treatment? Turk Psikiyatri Derg 2007;18:364-374
29. Yumru M, Savaş HA, Kokaçya MH, Virit O. Long acting risperidone in treatment of schizophrenia: a retrospective study. Klinik Psikofarmakoloji Bulteni-Bulletin Of Clinical Psychopharmacology 2007; 17:119-123
30. Inanli IC, Eren I. The effect of olanzapine on cognitive functions of patients with schizophrenia. Klinik Psikofarmakoloji Bulteni-Bulletin Of Clinical Psychopharmacology 2006; 16:213-222
31. Ayala M, Pizarro F, Méndez MA, Arredondo M, Araya M. Copper and liver function indicators vary depending on the female hormonal cycle and serum hormone binding globulin (SHBG) concentration in healthy women. Biol Trace Elem Res 2008; 121: 9-15
32. Grossman LS, Harrow M, Rosen C, Faull R. Sex differences in outcome and recovery for schizophrenia and other psychotic and nonpsychotic disorders. Psychiatr Serv. 2006; 57:844-850